Patent application

Tauriga Sciences Inc. Increases Size of Initial Production Run for its Delta 8 THC Infused Tauri-Gum Version

Retrieved on: 
Tuesday, April 20, 2021
United States patent law, Provisional application, Forward-looking statement, Patent application, Patent, XC2

On March 22, 2021, the Company announced that it had Converted its U.S.

Key Points: 
  • On March 22, 2021, the Company announced that it had Converted its U.S.
  • Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application.\xc2\xa0\xc2\xa0The Patent, filed with the U.S.P.T.O.
  • Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances.
  • You should not place undue reliance on these forward-looking statements.\n"

Tauriga Sciences Inc. Introduces its Newest Product Line: The Tauri-Gum Summertime Collection

Retrieved on: 
Monday, April 19, 2021
United States patent law, Provisional application, Forward-looking statement, Patent application, Patent, XC2

On March 22, 2021, the Company announced that it had Converted its U.S.

Key Points: 
  • On March 22, 2021, the Company announced that it had Converted its U.S.
  • Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application.\xc2\xa0\xc2\xa0The Patent, filed with the U.S.P.T.O.
  • Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances.
  • You should not place undue reliance on these forward-looking statements.\n"

Global Automated Guided Vehicles Sensor Technologies Market Report 2020: Advanced Sensors, Artificial Intelligence and Machine Learning Encourage AGV Development

Retrieved on: 
Thursday, April 1, 2021
Articles, Applications of computer vision, Automatic identification and data capture, Encodings, Skills, Computer vision, Machine vision, Learning, Barcode, Patent application, Surveillance, Automated guided vehicle

2.5 Patenting Trends for AGV: The US Leads the World in Patent Filing

Key Points: 

2.5 Patenting Trends for AGV: The US Leads the World in Patent Filing
3.3 Applications of Computer/Machine Vision IN AGVs: Seamless Movement of Objects without Human Intervention
3.4 Applications of Computer/Machine Vision in AGVs for Barcode Reading, Inspection, Surveillance, and Security

BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem® Program

Retrieved on: 
Wednesday, March 31, 2021
Intellectual property law, Branches of biology, Biology, Patent law, Patent application, United States Patent and Trademark Office, Stem cell

MELVILLE, N.Y., March 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office has issued a notice of allowance for a patent application related to the Companys metabolic ThermoStem Program.

Key Points: 
  • MELVILLE, N.Y., March 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office has issued a notice of allowance for a patent application related to the Companys metabolic ThermoStem Program.
  • The notice of allowance was issued on March 22, 2021 and is related to a new patent application not previously announced.
  • Claims granted under the new patent cover methodologies related to generating exosomes and brown adipocytes from human brown adipose-derived stem cells.
  • We are pleased to see that we have been granted an additional patent by the USPTO for our ThermoStem Program, said Lance Alstodt, the Companys CEO.

Össur Recognized by World Intellectual Property Organization (WIPO) as Leading Assistive Technology Development

Retrieved on: 
Thursday, March 25, 2021
Intangible assets, Intellectual property law, Articles, World Intellectual Property Organization, Assistive technology, Patent application, Wipo, Intellectual property, Patent, Education, Human behavior

REYKJAVIK, Iceland, March 25, 2021 /PRNewswire/ -- ssur (Nasdaq: OSSR), a global leader in the orthotics and prosthetics (O&P) industry with a rich history of ground-breaking innovations, has been recognized by the World Intellectual Property Organization (WIPO) for its intellectual property leadership in conventional mobility assistive technology.

Key Points: 
  • REYKJAVIK, Iceland, March 25, 2021 /PRNewswire/ -- ssur (Nasdaq: OSSR), a global leader in the orthotics and prosthetics (O&P) industry with a rich history of ground-breaking innovations, has been recognized by the World Intellectual Property Organization (WIPO) for its intellectual property leadership in conventional mobility assistive technology.
  • WIPO is a specialized agency of the United Nations and serves as the global forum for intellectual property policy, services, information and cooperation worldwide.
  • The WIPO Technology Trends Report 2021: Assistive Technologies is the first study to systematically investigate patenting and technology trends across assistive technology at scale, analyzing data on patent filings from 1998-2019.
  • ssur is also listed among the top applicants in patent filings for advanced prosthetics and exoskeletons, and ranks 12th in the world among top patent applicants for emerging mobility assistive technologies.

Össur Recognized by World Intellectual Property Organization (WIPO) as Leading Assistive Technology Development

Retrieved on: 
Thursday, March 25, 2021
Intangible assets, Intellectual property law, Articles, World Intellectual Property Organization, Assistive technology, Patent application, Wipo, Intellectual property, Patent, Education, Human behavior

REYKJAVIK, Iceland, March 25, 2021 /PRNewswire/ -- ssur (Nasdaq: OSSR), a global leader in the orthotics and prosthetics (O&P) industry with a rich history of ground-breaking innovations, has been recognized by the World Intellectual Property Organization (WIPO) for its intellectual property leadership in conventional mobility assistive technology.

Key Points: 
  • REYKJAVIK, Iceland, March 25, 2021 /PRNewswire/ -- ssur (Nasdaq: OSSR), a global leader in the orthotics and prosthetics (O&P) industry with a rich history of ground-breaking innovations, has been recognized by the World Intellectual Property Organization (WIPO) for its intellectual property leadership in conventional mobility assistive technology.
  • WIPO is a specialized agency of the United Nations and serves as the global forum for intellectual property policy, services, information and cooperation worldwide.
  • The WIPO Technology Trends Report 2021: Assistive Technologies is the first study to systematically investigate patenting and technology trends across assistive technology at scale, analyzing data on patent filings from 1998-2019.
  • ssur is also listed among the top applicants in patent filings for advanced prosthetics and exoskeletons, and ranks 12th in the world among top patent applicants for emerging mobility assistive technologies.

BioVaxys Expands Intellectual Property Portfolio

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Medicine, Bat virome, Virology, Vaccination, Clinical medicine, Patent application, Severe acute respiratory syndrome, Vaccine

BioVaxys President and Chief Operating Officer Kenneth Kovan states that "Because of the time and expense associated with developing novel products, BioVaxys places considerable importance on obtaining patent protection for new technologies, uses, and processes.

Key Points: 
  • BioVaxys President and Chief Operating Officer Kenneth Kovan states that "Because of the time and expense associated with developing novel products, BioVaxys places considerable importance on obtaining patent protection for new technologies, uses, and processes.
  • For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trades on the Frankfurt Bourse (FRA: 5LB) and US OTC: LMNGF.

BioVaxys Expands Intellectual Property Portfolio

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Medicine, Bat virome, Virology, Vaccination, Clinical medicine, Patent application, Severe acute respiratory syndrome, Vaccine

BioVaxys President and Chief Operating Officer Kenneth Kovan states that "Because of the time and expense associated with developing novel products, BioVaxys places considerable importance on obtaining patent protection for new technologies, uses, and processes.

Key Points: 
  • BioVaxys President and Chief Operating Officer Kenneth Kovan states that "Because of the time and expense associated with developing novel products, BioVaxys places considerable importance on obtaining patent protection for new technologies, uses, and processes.
  • For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trades on the Frankfurt Bourse (FRA: 5LB) and US OTC: LMNGF.

GBT Filed Continuation Applications For Database Management And Multi-Dimensional Microchip Patents

Retrieved on: 
Tuesday, March 23, 2021
Intellectual property law, United States patent law, United States Patent and Trademark Office, United States trademark law, Continuing patent application, Patent application, Patent

SAN DIEGO, March 23, 2021 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK:GTCH ) ("GBT or the Company), filed with the United States Patent and Trademark Office (USPTO) continuation applications for its mobile database sharing, publication # 20210081368 and multi-dimensional chip, publication # 20210083130 patents.Both applications were published on March 18, 2021.

Key Points: 
  • SAN DIEGO, March 23, 2021 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK:GTCH ) ("GBT or the Company), filed with the United States Patent and Trademark Office (USPTO) continuation applications for its mobile database sharing, publication # 20210081368 and multi-dimensional chip, publication # 20210083130 patents.Both applications were published on March 18, 2021.
  • The companys 3D microchip patent was granted as of December 1, 2020 by the USPTO as US patent U.S. Patent No.
  • GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents.
  • Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

Tauriga Sciences, Inc. Converts its U.S. Provisional Patent Application (Filed on March 17, 2020) to a U.S. Non-Provisional Patent Application

Retrieved on: 
Monday, March 22, 2021
United States patent law, Monopoly, Patent law, Provisional application, Patent application, Chewing gum, Patent, Term of patent in the United States, Business law, Outline of patents

Provisional Patent Application (filed on March 17, 2020) to a U.S. Non-Provisional Patent Application.

Key Points: 
  • Provisional Patent Application (filed on March 17, 2020) to a U.S. Non-Provisional Patent Application.
  • This Non-Provisional Patent Application relates to the Companys proposed Pharmaceutical Cannabinoid Chewing Gum Delivery System being developed to treat: Nausea Derived from Active Chemotherapy Treatment.
  • Also on March 17, 2021, to enhance its existing intellectual property (IP) portfolio, the Company filed an additional U.S.
  • On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum.